Surgical resection of vasoactive intestinal peptideoma with hepatic metastasis aids symptom palliation: A case report

Zhang, Xiaomei; Zhou, Lingli; Liu, Ying; Li, Wei; Gao, Hongkai; Wang, Yunan; Yao, Baoting; Jiang, Daming; Pei-jun, HU

doi:10.3892/etm.2016.3019

Cited by 6 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, 15 patients (15/30, 50%) were male and 15 patients (15/30, 50%) were female [Figure 2]. [23456789101112131415161718192021222324252627282930]…”

Section: Resultsmentioning

confidence: 99%

Prevalence of diagnostic methods and treatment modalities in vipoma patients: A rare cause of hormone-mediated diarrhea

Amiri

2019

Indian J Endocr Metab

View full text Add to dashboard Cite

Introduction: VIPoma is a neuroendocrine tumor that secrets vasoactive intestinal peptide and produces a well-defined clinical syndrome characterized by watery diarrhea, hypokalemia, hypochlorhydria and metabolic acidosis. The aim of this study to investigate clinical studies about diagnostic and therapeutic modalities of vipoma patients. In this retrospective study, all patients of vipoma were investigated. Clinical features, laboratory data at initial presentation, management and outcomes were collected. Subjects and Methods: The paper has written based on searching PubMed and Google Scholar to identify potentially relevant articles or abstracts. Categorical variables as percentage and continuous variables were reported as mean ± standard deviation (SD). Results: All the patients presented with watery diarrhea (30/30, 100%) and dehydration was reported in 33.3% of them. Prevalence of laboratory findings in these patients were assessed for hypokalaemia (25/30, 83.3%), metabolic acidosis (9/30, 33.6%), hypochloremia and achlorhydria (2/30, 6.6%). Elevated VIP levels have been seen in 73.3% patients with mean values of 882.85 ± 1134.87 pg/ml. Prevalence of diagnostic methods included CT scan in 19 patients (19/30, 63.3%), ultrasonography (15/50, 50%), and somatostatin receptor scintigraphy (8/30, 26.6%). Medical treatments included somatostatin and analogues in 18 patients (18/30, 60%). Surgery included less percentage of treatment in these patients. Conclusion: CT scan can be used as a reliable modality for diagnosis of vipoma and somatostatin analogues can be used as the most effective treatment in vipoma patients. Surveillance of these patients needs to close monitoring of patients via history, physical examination, laboratory and imaging.

show abstract

“…Of these, 15 patients (15/30, 50%) were male and 15 patients (15/30, 50%) were female [Figure 2]. [23456789101112131415161718192021222324252627282930]…”

Section: Resultsmentioning

confidence: 99%

Prevalence of diagnostic methods and treatment modalities in vipoma patients: A rare cause of hormone-mediated diarrhea

Amiri

2019

Indian J Endocr Metab

View full text Add to dashboard Cite

show abstract

“…Both studies and case reports have reported the successful use in patients with VIPomas of the control of the symptoms of the hormone-excess state by using: tyrosine kinase inhibitor sunitinib[47, 49]; liver directed therapies including TACE/TAE[70, 100, 173, 174, 184, 185]; radioembolization[70, 150], RFA [81, 83, •186, 187, 188]; by increasing the dosage of octreotide/Lanreotide in refractory cases[185] and the use of cytoreductive surgery[100, 102, 134, 158, 160, 174, •186, 189]. …”

Section: Summary Of Recent Advances In Management Of Specific Hormmentioning

confidence: 99%

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies

Ito¹,

Lee²,

Jensen³

2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction Neuroendocrine tumors(NETs), once thought rare, are increasing in frequency in most countries and receiving increasing-attention. NETs present two-treatment problems. A proportion is functional, hormone-excess-state(F-NET), each of which must be treated. Recently, there are many advances, well-covered in reviews/consensus papers on imaging-NETs;new, novel anti-tumor treatments and understanding their pathogenesis. However, little attention has been paid to advances in the treatment of the hormone-excess-state. These advances are usually reported in case-series, and case-reports with few large studies. In this paper these advances are reviewed. Areas covered Advances in the last 5-years are concentrated on, but a review up to 10-years was performed. PubMed and other databases(Cochrane, etc) were searched for F-NET-syndromes including carcinoid-syndrome, as well as meeting-abstracts on NETs. All advances that controlled hormone-excess-states or facilitated-control were covered. These include new medical-therapies[serotonin-synthesis inhibitors(telotristat), Pasireotide, new agents for treating ACTHomas], increased dosing with conventional therapies(octreotide-LAR, Lanreotide-Autogel), mTor inhibitors(everolimus), Tyrosine-kinase inhibitors(sunitinib), cytoreductive surgery, liver-directed therapies(embolization, chemoembolization, radioembolization, RFA), peptide radio-receptor-therapy(PRRT) and 131I-MIBG, ablation of primary F-NETs. Expert Opinion Although many of the newer therapies controlling the hormone-excess-states in F-NETs are reported in relatively few patients, all the approaches show promise. Their description also generates some controversies/unresolved areas, such as the order of these new treatments, their longterm-efficacy, and effectiveness of combinations which may require large, controlled studies.

show abstract

“…Somatostatin analogues (SSAs) inhibit VIP secretion and are used to control symptoms[ 15 ]. Somatostatin is a peptide that reduces the secretion of an ample set of hormones[ 50 ]. Various studies on functional NETs have shown that controlling hormone levels is crucial to reduce patients’ morbidity and mortality[ 51 ].…”

Section: Treatment/managementmentioning

confidence: 99%

Vasoactive intestinal peptide secreting tumour: An overview

Cidon¹

2022

WJGO

View full text Add to dashboard Cite

Vasoactive intestinal peptide (VIP) secreting tumour (VIPoma) is a rare functional neuroendocrine tumour that typically arises from pancreatic islet cells. These present as sporadic, solitary pancreatic neoplasias with an estimated incidence of one in ten million individuals per year. Only around 5% of VIPomas are associated with multiple endocrine neoplasia type I syndrome. Excessive VIP secretion produces a clinical syndrome characterized by refractory watery diarrhoea, hypokalemia and metabolic acidosis. These coupled with elevated plasma levels of VIP are diagnostic. The majority of VIPomas are malignant and have already metastasized at the time of diagnosis (60%). Metastases occur most frequently in the liver, or regional lymph nodes, lungs, kidneys and bones. Some reports of skin metastases have been documented. Complete surgical resection continues to be the only potentially curative treatment. However, when the neoplasia cannot be excised completely, surgical debulking may provide palliative benefit. Other palliative options have included recently the peptide receptor radionuclide therapy which has shown to be effective and well-tolerated. This article will review all aspects of pancreatic VIPomas highlighting aspects such as clinical presentation, diagnosis and management.

show abstract

Surgical resection of vasoactive intestinal peptideoma with hepatic metastasis aids symptom palliation: A case report

Cited by 6 publications

References 13 publications

Prevalence of diagnostic methods and treatment modalities in vipoma patients: A rare cause of hormone-mediated diarrhea

Prevalence of diagnostic methods and treatment modalities in vipoma patients: A rare cause of hormone-mediated diarrhea

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies

Vasoactive intestinal peptide secreting tumour: An overview

Contact Info

Product

Resources

About